# CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

> **NCT00562419** · PHASE2 · UNKNOWN · sponsor: **Adnexus, A Bristol-Myers Squibb R&D Company** · enrollment: 72 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors
- Recurrent Glioblastoma Multiforme

## Interventions

- **DRUG:** CT-322
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00562419
- **Lead sponsor:** Adnexus, A Bristol-Myers Squibb R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2010-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562419, "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00562419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*